Holen Sie sich die Stockscreener-App
87.12
0.79%
0.68
Handel nachbörslich:
91.47
4.35
+4.99%
Schlusskurs vom Vortag:
$86.44
Offen:
$80.22
24-Stunden-Volumen:
2.33M
Relative Volume:
4.66
Marktkapitalisierung:
$4.65B
Einnahmen:
$144.75M
Nettoeinkommen (Verlust:
$-53.89M
KGV:
-22.00
EPS:
-3.96
Netto-Cashflow:
$-42.88M
1W Leistung:
-0.15%
1M Leistung:
+11.36%
6M Leistung:
+65.34%
1J Leistung:
+95.21%
1-Tages-Spanne:
$77.00
$87.74
1-Wochen-Bereich:
$77.00
$91.20
52-Wochen-Spanne:
$43.50
$97.54
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
BofA raises Arcellx price target to $100 on positive data - Investing.com
Arcellx (NASDAQ:ACLX) Shares Gap DownHere's Why - MarketBeat
Arcellx issues updates on anito-cel clinical trials (NASDAQ:ACLX) - Seeking Alpha
Mirae Asset Global Investments Co. Ltd. Acquires 347 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx : to Present Clinical Data for Its Phase 1 and iMMagine 1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine 3 Study Form 8 K - Marketscreener.com
Arcellx reports promising results for myeloma treatment - Investing.com
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Marketscreener.com
Arcellx's Multiple Myeloma Drug Shows 95% Response Rate in Phase 2 Trial, Strong Safety Data | ACLX Stock News - StockTitan
Cancer cell therapy from Arcellx, Gilead shows promise in early data - Yahoo Finance
Arcellx, Inc. (NASDAQ:ACLX) Shares Purchased by Harbor Capital Advisors Inc. - MarketBeat
abrdn plc Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Earns “Buy” Rating from Needham & Company LLC - Defense World
Arcellx (ACLX) Surged in Q3. Here’s Why - Insider Monkey
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 5.3% - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 5.3% - Defense World
Arcellx shares target increased, Outperform upheld as ASH data release nears - Investing.com India
A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St
Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth By Investing.com - Investing.com Australia
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT
Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth - Investing.com India
Arcellx director Kavita Patel sells $134,535 in stock - Investing.com
Arcellx, Inc. (NASDAQ:ACLX) Director Sells $134,535.00 in Stock - MarketBeat
Arcellx director Kavita Patel sells $134,535 in stock By Investing.com - Investing.com Canada
Cracking The Code: Understanding Analyst Reviews For Arcellx - Benzinga
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Arcellx (NASDAQ:ACLX) Reaches New 52-Week High After Analyst Upgrade - Defense World
Arcellx (NASDAQ:ACLX) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Canaccord Genuity Group Increases Arcellx (NASDAQ:ACLX) Price Target to $115.00 - Defense World
Stifel Nicolaus Increases Arcellx (NASDAQ:ACLX) Price Target to $122.00 - Defense World
(ACLX) Trading Advice - Stock Traders Daily
Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism - Investing.com India
4 Analysts Assess Arcellx: What You Need To Know - Benzinga
Arcellx (NASDAQ:ACLX) PT Raised to $122.00 - MarketBeat
Stifel lifts Arcellx stock target, keeps buy rating on safety profile optimism By Investing.com - Investing.com South Africa
Arcellx (NASDAQ:ACLX) PT Raised to $115.00 at Canaccord Genuity Group - MarketBeat
Arcellx stock soars to all-time high of $88.67 amid robust growth - Investing.com Australia
Examining the Potential Price Growth of Arcellx Inc (ACLX) - Knox Daily
Arcellx (NASDAQ:ACLX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by AQR Capital Management LLC - Defense World
12,035 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by SG Americas Securities LLC - MarketBeat
Arcellx Inc (ACLX) may enjoy gains as insiders got busy in the recent days - Knox Daily
ACLX’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
(ACLX) Technical Data - Stock Traders Daily
Arcellx (NASDAQ:ACLX) Shares Gap UpHere's What Happened - MarketBeat
Redburn sees Arcellx stock gaining from innovative CAR-T platform and strong growth - Investing.com Canada
The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx (NASDAQ:ACLX) Earns Buy Rating from Analysts at Redburn Atlantic - MarketBeat
The Manufacturers Life Insurance Company Boosts Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):